4-(2-chlorophenyl)-5-cyano-N-(2-methoxyphenyl)-2-methyl-6-(propylthio)-1,4-dihydropyridine-3-carboxamide | 330558-01-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2-chlorophenyl)-5-cyano-N-(2-methoxyphenyl)-2-methyl-6-(propylthio)-1,4-dihydropyridine-3-carboxamide
• 英文别名: 4-(2-chlorophenyl)-5-cyano-N-(2-methoxyphenyl)-2-methyl-6-propylsulfanyl-1,4-dihydropyridine-3-carboxamide
• CAS: 330558-01-5
• 化学式: C₂₄H₂₄ClN₃O₂S
• 分子量: 453.992
• InChiKey: WGPNNQFTTJDXBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  99.4
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• MINERALOCORTICOID RECEPTOR MODULATORS
  申请人：Brandish Philip E.

  公开号：US20100261765A1

  公开（公告）日：2010-10-14

  The present invention relates to dihydropyridine mineralocorticoid receptor modulating compounds having the structure: and their use in treating cardiovascular events.

  本发明涉及具有以下结构的二氢吡啶矿物质皮质激素受体调节化合物及其在治疗心血管事件中的应用。
• PHARMACEUTICAL COMPOSITIONS FOR PREVENTING GLUCOCORTICOID-INDUCED CORNEAL OR SKIN THINNING
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

  公开号：US20160136183A1

  公开（公告）日：2016-05-19

  The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof. The invention also relates to a topical pharmaceutical composition comprising an amount of at least one glucocorticoid and an amount of at least one mineralocorticoid receptor antagonist or inhibitor of MR expression for use in a method for treating an inflammatory skin disease or an inflammatory disease of the cornea or of the anterior segment of the eye in a subject in need thereof.
• US9730948B2
  申请人：——

  公开号：US9730948B2

  公开（公告）日：2017-08-15
• [EN] PHARMACEUTICAL COMPOSITIONS FOR PREVENTING GLUCOCORTICOID-INDUCED CORNEAL OR SKIN THINNING<br/>[FR] COMPOSITIONS PHARMACEUTIQUES POUR LA PRÉVENTION DE L'AMINCISSEMENT DE LA CORNÉE OU DE LA PEAU INDUIT PAR DES GLUCOCORTICOÏDES
  申请人：INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE

  公开号：WO2014202744A1

  公开（公告）日：2014-12-24

  The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof. The invention also relates to a topical pharmaceutical composition comprising an amount of at least one glucocorticoid and an amount of at least one mineralocorticoid receptor antagonist or inhibitor of MR expression for use in a method for treating an inflammatory skin disease or an inflammatory disease of the cornea or of the anterior segment of the eye in a subject in need thereof.
• [EN] METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHOROIDAL NEOVASCULARISATION<br/>[FR] MÉTHODES ET COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITEMENT DE LA NÉOVASCULARISATION CHOROÏDIENNE
  申请人：INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE)

  公开号：WO2017064121A1

  公开（公告）日：2017-04-20

  The present invention relates to methods and pharmaceutical compositions for the treatment of choroidal neovascularisation. In particular, the present invention relates to a method of treating choroidal neovascularisation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a mineralocorticoid receptor antagonist.